Cmax

Максимальная концентрация.

Навигация по записям

Следующая запись: биоэквивалентность

Найти:

Свежие записи

Long WS Wide: или про то, как выполнить анализ разницы изменений между группами
Частые вопросы: Регистрация и экспертиза по правилам ЕАЭС
Главные ошибки при формировании базы данных в MS Excel
Тест ClinicalTrialUtilities и ReplicateBE на Raspberry Pi 4
Julia:ReplicateBE – release 0.2.0

Галерея

Anesthetic and Analgesic Drug Products Advisory Committee Roster
Source: FDA - What's New: Drugs RSS Feed Published on 2023-04-01 By FDA
FDA approves dabrafenib with trametinib for pediatric patients with low-grade glioma with a BRAF V600E mutation
Source: FDA - What's New: Drugs RSS Feed Published on 2023-03-31 By FDA
Coronavirus (COVID-19) | CBER-Regulated Biologics
Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2023-03-31 By FDA
Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Atovaquone Oral Suspension, USP 750mg/5mL Due to Potential Bacillus Cereus Contamination in the Product
Source: FDA - What's New: Drugs RSS Feed Published on 2023-03-31 By FDA
We Are Hiring
Source: FDA - What's New: Drugs RSS Feed Published on 2023-03-31 By FDA
Drug Disposal: Questions and Answers
Source: FDA - What's New: Drugs RSS Feed Published on 2023-03-31 By FDA
Human medicines European public assessment report (EPAR): Qarziba (previously Dinutuximab beta EUSA and Dinutuximab beta Apeiron), dinutuximab beta, Neuroblastoma, Date of authorisation: 08/05/2017, Revision: 14, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2023-03-31
Guideline on Quality Aspects of Pharmaceutical Veterinary Medicines for administration via drinking water - Draft Annex on compatibility studies between veterinary medicinal products and biocidal products
Source: EMA - Scientific guidelines (human and veterinary) Published on 2023-03-31
Human medicines European public assessment report (EPAR): Dzuveo, sufentanil, Pain, Date of authorisation: 25/06/2018, Revision: 6, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2023-03-31
National Minority Health Month: Better Health Through Better Understanding
Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2023-03-31 By FDA
Human medicines European public assessment report (EPAR): Kisplyx, lenvatinib, Carcinoma, Renal Cell, Date of authorisation: 25/08/2016, Revision: 18, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2023-03-31
Identification of Medicinal Products — Implementation and Use
Source: FDA - What's New: Drugs RSS Feed Published on 2023-03-31 By FDA
Newly Added Guidance Documents
Source: FDA - What's New: Drugs RSS Feed Published on 2023-03-31 By FDA
Human medicines European public assessment report (EPAR): Lydisilka, estetrol,drospirenone, Contraceptives, Oral, Date of authorisation: 19/05/2021, Revision: 3, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2023-03-31
Human medicines European public assessment report (EPAR): Grasustek, pegfilgrastim, Neutropenia, Date of authorisation: 20/06/2019, Revision: 4, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2023-03-31

Предыдущие записи

Тема: Scaffold от Danny Cooper.